This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veeva Expands Market Reach Through Targeted Strategic Partnerships
by Harshit Gupta
VEEV gains momentum in 2025 with strategic partnerships fueling growth in AI, clinical research, and compliance.
VEEV Rises 29% in 3 Months: Should You Buy the Stock Now or Wait?
by Harshit Gupta
Veeva Systems gains momentum as strong earnings, Vault CRM growth, and new AI tools reinforce its life sciences edge.
VEEV Integrates GenAI in Vault Platform to Drive Workflow Automation
by Harshit Gupta
Veeva's new AI layer in Vault boosts automation and deepens pharma reliance, sharpening its edge in life sciences tech.
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
by Moumi Mondal
TEM is scaling fast; Data and Services revenues soar 43%, fueled by big-name pharma and AI model deals.
Doximity Declines 4.4% in a Month: How to Play the Stock Now?
by Indrajit Bandyopadhyay
DOCS slips 4.4% in a month despite strong Q4 results, margin gains and raised guidance -- is there a buying opportunity?
Investing in IQVIA (IQV)? Don't Miss Assessing Its International Revenue Trends
by Zacks Equity Research
Evaluate IQVIA's (IQV) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
IQVIA (IQV) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for IQVIA (IQV) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IQVIA Earnings & Revenues Beat Estimates in Q1, Increase Y/Y
by Zacks Equity Research
IQV's top line in the first quarter of 2025 benefits from the Research and Development, and Technology and Analytics segments.
IQVIA Holdings (IQV) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
IQVIA (IQV) delivered earnings and revenue surprises of 2.66% and 1.55%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Gears Up to Report Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Growth across the R&DS and TAS segments is anticipated to have boosted IQV's top line in the first quarter of 2025.
IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Evaluate the expected performance of IQVIA (IQV) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
RxSight, Inc. (RXST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last?
by Zacks Equity Research
IQVIA (IQV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Paychex Q3 Earnings & Revenues Surpass Estimates, Increase Y/Y
by Zacks Equity Research
PAYX's top line in the third quarter of fiscal 2025 gains from the Management Solutions, and PEO and Insurance Solutions segments.
Here's Why Investors Must Hold IQV Stock in Their Portfolios Now
by Zacks Equity Research
The IQV stock is benefiting from partner retention, acquisition and investment in AI-led innovation.
ABM Shares Decline 4% Despite Reporting Q1 Earnings & Revenue Beat
by Zacks Equity Research
ABM's top line in the first quarter of fiscal 2025 improves on the back of y/y growth in aviation, education and technical solutions segments.
IQVIA Gains From Diversified Client Base Despite Low Liquidity Woes
by Zacks Equity Research
The IQV stock benefits from its healthcare-centric IT infrastructure across the globe and a treasure trove of data distinguishing it from its competitors.
PRTH Gears Up to Report Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Healthy reseller relationships are expected to have aided Priority Technology's top line in the fourth quarter of 2024.
GDOT's Earnings and Revenues Surpass Estimates in Q4
by Zacks Equity Research
GDOT's fourth-quarter 2024 earnings and revenues increase on a year-over-year basis.
IQVIA Holdings (IQV) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight
by Urmimala Biswas
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.
Waste Connections Q4 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
WCN's top line gains from improved segmental performances in the fourth quarter of 2024.